Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Bevacizumab for CNV in VKH Disease
NCT02015351Completed
- Sponsor
- Universidade de São Paulo
- Start
- Sep 2012
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab in choroidal neovascularization (CNV), sponsored by Universidade de São Paulo. Primary endpoints: Visual Acuity change at 6 months, Change in central foveal thickness at 6 months and 1 more. Started Sep 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02015351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015351.